---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-031669"
form_type: "8-K"
ticker: "FHTX"
cik: "0001822462"
company_name: "Foghorn Therapeutics Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:59:49.778389+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Foghorn Q1 net loss $19.9M, cash $183.6M; FHD-909 Phase 1 on track; IND for two degraders expected 2027

## Summary
- Q1 2026 net loss $19.9M (vs $18.8M loss Q1 2025); collaboration revenue $3.3M (down from $6.0M).
- Cash, equivalents & marketable securities $183.6M as of Mar 31, 2026; cash runway into H1 2028.
- Lead program FHD-909 Phase 1 dose-escalation on track; preclinical combo with anti-PD-1 showed complete tumor regression and immune memory.
- IND expected 2027 for Selective CBP degrader FHT-171 and Selective EP300 degrader; ARID1B degrader advancing to in vivo proof-of-concept in 2026.
- R&D expenses declined to $18.3M (from $21.6M) driven by lower Lilly-partnered program costs and facilities expenses.

## SEC filing metadata
- accession: 0001628280-26-031669
- form_type: 8-K
- ticker: FHTX
- cik: 0001822462
- company_name: Foghorn Therapeutics Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822462/000162828026031669/0001628280-26-031669-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822462/000162828026031669/fhtx-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-031669
- JSON: https://secwatch.observer/filing/0001628280-26-031669.json
- Plain text: https://secwatch.observer/filing/0001628280-26-031669.txt

## Source-grounded claims
- claim_id: 01da4ed373bdc710440991ec73b518fb5cd860c8
  claim: Foghorn Therapeutics Inc. reported financial results for the quarter ended March 31, 2026.
  evidence_excerpt: On May 7, 2026, Foghorn Therapeutics Inc. (the “Company”) issued a press release announcing certain of the Company’s financial results for the quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1822462/000162828026031669/0001628280-26-031669-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.